CNR1 and myeloid sarcoma: To strengthen our conclusions, however, the impact of CNR1 (AAT)n repeat polymorphism on CB1R mRNA levels should also be addressed, along with measurements in a larger independent population of MS patients, by using other CB1R-specific antibodies, and in healthy individuals.